| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705054 | Ophthalmology | 2017 | 12 Pages |
Abstract
Change in BCVA in STGD1 patients over a 12-month period was small, but varied depending on baseline BCVA. Given the slow change during 1 year, BCVA is unlikely to be a sensitive outcome measure for STGD1 treatment trials with 1 year's duration.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Xiangrong PhD, Rupert W. MD, Artur V. PhD, Michel MD, José-Alain MD, Beatriz MS, Mohamed MD, Ann M. PhD, Sheila K. PhD, Janet K. PharmD, Hendrik P.N. MD, MA, ProgStar Study Group ProgStar Study Group,